PC
SRPT icon

PointState Capital’s Sarepta Therapeutics SRPT Stock Holding History

PointState Capital’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-87,000
Closed -$1.7M – 131
2016
Q1 		$1.7M Buy
+87,000
New +$1.52M 0.05% 79

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

PointState Capital's SRPT Position: Q3 2018 in Review

PointState Capital sold out of Sarepta Therapeutics (SRPT) in Q3 2018, closing a stake of 198,900 shares — an estimated $26.3M sold.

PointState Capital first reported a position in SRPT in Q3 2013 and held it in 17 quarters. The position peaked at $27M in Q4 2017. 344 funds tracked by Wall St. Rank hold SRPT as of Q3 2018.

  • PointState Capital reported no remaining Sarepta Therapeutics position as of Q3 2018 after selling out during the quarter.
  • PointState Capital sold 198,900 Sarepta Therapeutics shares in Q3 2018, an estimated $26.3M.
  • PointState Capital first reported a position in Sarepta Therapeutics in Q3 2013 and held it in 17 quarters.
  • PointState Capital's Sarepta Therapeutics position peaked at $27M in Q4 2017.
  • 344 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2018.

Based on PointState Capital's 13F filing for Q3 2018, filed 14 Nov 2018.